BRAF mutations, mostly non-V600E, account for 1–4% of NS-NSCLC [57] and lead to the activation of the MAPK pathway downstream of EGFR and RAS, and this kinase can be targeted by the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametimib [58,59]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.